Press coverage about ConforMIS (NASDAQ:CFMS) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ConforMIS earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 45.2307621256749 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Undulating Stocks: Direxion Daily Small Cap Bear 3X ETF (NYSE:TZA), ConforMIS, Inc. (NASDAQ:CFMS), BBX Capital … (thestreetpoint.com)
- Yesterday’s Sizzlers: Entravision Communications Corporation (NYSE:EVC), ConforMIS, Inc. (NASDAQ:CFMS), Lions … (journalfinance.net)
- Rolling Three Stocks: ConforMIS, Inc. (NASDAQ:CFMS), NanoViricides, Inc. (NYSE:NNVC), China Lending … (thestreetpoint.com)
- Investment Grade Analysis On Conformis, Inc. (NasdaqGS:CFMS) Shares (parkcitycaller.com)
- Latest Tally Of Analyst Opinions: ConforMIS, Inc. (NASDAQ:CFMS), Earthstone Energy, Inc. (NYSE:ESTE), Forward … (journalfinance.net)
A number of brokerages have recently issued reports on CFMS. Zacks Investment Research cut ConforMIS from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. Oppenheimer reiterated a “buy” rating on shares of ConforMIS in a research note on Thursday, March 22nd. Canaccord Genuity reissued a “hold” rating on shares of ConforMIS in a report on Monday, March 12th. Cowen started coverage on ConforMIS in a report on Wednesday, February 21st. They set an “outperform” rating and a $4.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and set a $3.00 target price on shares of ConforMIS in a report on Thursday, May 3rd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $3.58.
Shares of ConforMIS traded up $0.02, reaching $1.33, during trading on Friday, Marketbeat.com reports. 322,100 shares of the company’s stock were exchanged, compared to its average volume of 593,300. The company has a current ratio of 5.95, a quick ratio of 5.34 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $81.62 million, a PE ratio of -1.07 and a beta of 1.02. ConforMIS has a twelve month low of $1.15 and a twelve month high of $5.73.
ConforMIS (NASDAQ:CFMS) last posted its earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $19.66 million for the quarter, compared to analyst estimates of $19.51 million. ConforMIS had a negative return on equity of 83.49% and a negative net margin of 62.63%. sell-side analysts predict that ConforMIS will post -0.83 EPS for the current fiscal year.
In other ConforMIS news, Director Philipp Lang sold 651,212 shares of the company’s stock in a transaction on Monday, April 30th. The stock was sold at an average price of $1.38, for a total value of $898,672.56. Following the transaction, the director now directly owns 95,055 shares of the company’s stock, valued at approximately $131,175.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bradley Langdale sold 75,764 shares of the company’s stock in a transaction on Thursday, April 26th. The shares were sold at an average price of $1.52, for a total value of $115,161.28. Following the completion of the transaction, the director now directly owns 95,055 shares in the company, valued at $144,483.60. The disclosure for this sale can be found here. Insiders have sold a total of 1,027,405 shares of company stock worth $1,438,261 over the last three months. 7.59% of the stock is owned by insiders.
ConforMIS Company Profile
ConforMIS, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.